September 2022 in “Concilium” This study found that scalp cooling effectively prevented chemotherapy-induced alopecia in patients, with a higher success rate observed in those who did not receive anthracyclines, although some experienced scalp pain and other mild adverse effects.
August 2026 in “PLoS ONE” This study will evaluate the clinical efficacy, patient-reported outcomes, and economic impact of the PAXMAN® PSCS 2 automated scalp cooling system versus standard cold-cap therapy to prevent chemotherapy-induced hair loss in women with localized breast cancer during anthracycline and taxane treatment.
January 2019 in “Research Square (Research Square)” In this study, researchers will conduct a randomized, double-blind, multi-center clinical trial to assess the effectiveness of YH0618 granule in preventing chemotherapy-induced hair loss among breast cancer patients, aiming to understand its mechanism related to kidney deficiency in Chinese Medicine. Results are not yet reported.
September 2025 in “PubMed” In this Delphi study, international experts established consensus-based guidelines for diagnosing and managing persistent chemotherapy-induced alopecia (pCIA), recommending prevention through scalp cooling and early use of minoxidil, while advising against bicalutamide and certain finasterides for breast cancer patients due to safety concerns.
5 citations
,
August 2024 in “Clinical & Translational Oncology” This review provides a comprehensive overview of multidisciplinary dermo-aesthetic interventions for breast cancer patients, aiming to establish safe protocols involving various specialists to improve quality of life, although consultation with an oncologist before treatment is advised.
